Brief: ABVC Biopharma Announces Enrollment Progress For ADHD Phase II Part 2 Clinical Study
01/06/2022 13:31
June 1 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA ANNOUNCES ENROLLMENT PROGRESS FOR ADHD
PHASE II
PART 2 CLINICAL STUDY
* ABVC BIOPHARMA INC- SINCE FIRST SUBJECT BEGAN TREATMENT ON
MAY
10, 2022, 13 ADDITIONAL SUBJECTS HAVE BEEN ENROLLED IN STUDY
Source text for Eikon: ID:nGNXbdXnnj
Further company coverage: ABVC.O
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner